Quarterly Consolidated Statement Of Cash Flows

Kidswell Bio Corporation - Filing #7246134

Concept 2024-04-01 to
2025-03-31
As at
2025-03-31
2024-04-01 to
2025-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
651,563,000 JPY
72,867,000 JPY
-1,420,527,000 JPY
Depreciation
900,000 JPY
Impairment losses
6,444,000 JPY
Interest and dividend income
-767,000 JPY
Interest expenses
39,379,000 JPY
Decrease (increase) in trade receivables
-385,782,000 JPY
Decrease (increase) in inventories
-599,438,000 JPY
Increase (decrease) in trade payables
141,837,000 JPY
Other, net
54,207,000 JPY
Subtotal
984,244,000 JPY
Interest and dividends received
767,000 JPY
Interest paid
-46,752,000 JPY
Income taxes paid
-1,551,000 JPY
Net cash provided by (used in) operating activities
936,707,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-6,444,000 JPY
Purchase of investment securities
-14,472,000 JPY
Proceeds from sale of investment securities
88,948,000 JPY
Net cash provided by (used in) investing activities
65,077,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-737,040,000 JPY
Net cash provided by (used in) financing activities
-240,061,000 JPY
Effect of exchange rate change on cash and cash equivalents
2,299,000 JPY
Net increase (decrease) in cash and cash equivalents
764,024,000 JPY
Cash and cash equivalents
2,995,435,000 JPY
2,231,411,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.